Merck Global Health Innovation Fund
VC Fund
Whitehouse Station, United States
Merck Global Health Innovation Fund is a VC fund in Whitehouse Station focused on Health Care and Biotechnology. Merck Global Health Innovation Fund (Merck GHI) is evolving corporate healthcare venture capital globally by utilizing their healthcare ecosystem strategy. This investment strategy connects innovative companies with complementary technologies to develop integrated healthcare solutions.Merck GHI has $500M under management and provides growthcapital to emerging healthcare technology companies worldwide while leveraging the vast R&D-based, global resources of Merck.With a vision that data will be the currency in healthcare, GHI invests broadly in digital health. GHI invests in platform companies with proven technologies or business models where Merck's expertise and perspectives can accelerate revenue growth and enhance value creation. Since late 2010, Merck GHI has made over 20 investments in Digital Health companies.
- Total investments:
- 113
- Last investment:
- Lead investor:
- 46%
Last updated:
For AI agents: llms.txt
Industries Merck Global Health Innovation Fund invests in
Stages Merck Global Health Innovation Fund invests in
Countries Merck Global Health Innovation Fund invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 9 contacts → | |||
Round size
- Series A
- $8M–$32M
- Series B
- $9M–$98M
Investment Focus
Industry
- Health Care 47 (42%)
- Biotechnology 25 (22%)
- Information Technology 17 (15%)
- Medical 15 (13%)
- Software 14 (12%)
Stage
- Series B 27 (24%)
- Series A 14 (12%)
- Funding Round 13 (12%)
- Series C 11 (10%)
- Venture - Series Unknown 11 (10%)
Country
- United States 58 (51%)
- Canada 3 (3%)
- United Kingdom 2 (2%)
- India 1 (1%)
- Mexico 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Bill Taranto
Founder, President & General Partner
|
Founder, President & General Partner | Total investments: 1 | Find email | |
Bill Taranto
Founder, President & General Partner
|
Founder, President & General Partner | Total investments: 2 | Find email | |
Dave Stevenson
Managing Director
|
Managing Director | Total investments: 2 | Find email | |
Joe Volpe
Managing Director and Founding Partner
|
Managing Director and Founding Partner | Total investments: 15 | Find email | |
David M. Rubin
Managing Director
|
Managing Director | Total investments: 21 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
N-Power Medicine
|
N-Power Medicine specializes in drug development and clinical research. | $32M / Series B / Sep 01, 2026 | |
Faro AI
|
Clinical protocols are scientific decisions wrapped in administrative burden. The Faro system handles the tedious work better left for a computer, freeing clinical researchers to focus on the important decisions that drive clinical value. | $37.3M / Series B / Aug 26, 2026 | |
DropGenie
|
DropGenie is building connected hardware to automate gene editing. They are accelerating the pace of discovery through the generation of standardized and compatible scientific information. | $3.2M / Seed / Jun 22, 2026 | |
Unnatural Products
|
Unnatural Products is a startup pairing AI with chemistry to create treatments for drug targets. Its AI-enhanced technology platform creates entirely new drugs by engineering passively permeable, macrocyclic peptides that access traditionally undruggable targets.Unnatural Products was founded in 2017 and is headquartered in Santa Cruz,California. | $45M / Series B / Mar 16, 2026 | |
Octave
|
Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States. | $35.6M / Series C / Sep 04, 2025 | |
PreciseDx
|
PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, enabling better and more personalized treatment and outcomes. Clinical teams can rely on PreciseDx for unmatched insights and actionable intelligence in determining the best treatment for each patient.Combining the power of artificial intelligence with its proprietary Morphology Feature Array™, PreciseDx creates disease-specific assays that deliver new levels of pathology information and insight on each patient's risk profile and likely outcomes to aid in treatment decision-making. | $11.2M / Series B / Jun 05, 2025 | |
Redica Systems
|
Redica Systems uses AI and machine learning to provide Quality and Regulatory Intelligence (QRI) solutions to life sciences companies. The company's data analytics platform is designed for regulated industries to enhance quality and regulatory compliance. It connects Quality Assurance with Regulatory Surveillance to structure unstructuredcontent, delivering insights for quality and safety professionals. | $5M / May 09, 2025 | |
Variational AI
|
Variational AI uses state-of-the-art machine learning in a data-efficient method to rapidly generate novel and diverse compounds that are optimized for multiple properties to avoid the most common causes of drug attrition and increase clinical probability of success. Variational AI works with leading biopharmaceutical partners and is developing itsown internal pipeline. | $5.5M / Seed / Feb 20, 2025 | |
Evaxion Biotech
|
Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currentlyincludes three patient-specific cancer immunotherapies, two of which are in Phase I/IIa clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections with one program currently in preclinical development against S. aureus (including Methicillin-resistant S. aureus) induced skin and soft tissue infections. | $10.8M / Post-IPO Equity / Jan 30, 2025 | |
Ash
|
Ash is a leading at-home health testing platform expanding care to reach those most in need. Working closely with our partners, we tailor end-to-end testing solutions that meet the unique needs of any health organization’s population.Our strength comes from our unmatched understanding of people—whether that means learning the best ways to reachthem or innovating a new way to keep them connected and cared for. We use our deep knowledge to develop field-tested best practices that engage hard-to-reach patients and members where they are. Because when people come first, better health outcomes are possible for all. | $10M / Series A / Oct 16, 2024 | |
| See all 113 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Merck Global Health Innovation Fund invest in?
Merck Global Health Innovation Fund invests primarily in Health Care, Biotechnology and Information Technology startups, most often at Series B and Series A stage. Most of the 113 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Merck Global Health Innovation Fund's check size?
Merck Global Health Innovation Fund typically joins rounds of $8M–$32M at Series A and $9M–$98M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Merck Global Health Innovation Fund participates in.
How do I contact Merck Global Health Innovation Fund?
Public channels for Merck Global Health Innovation Fund include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Merck Global Health Innovation Fund?
The team at Merck Global Health Innovation Fund includes Bill Taranto (Founder, President & General Partner), Bill Taranto (Founder, President & General Partner) and Dave Stevenson (Managing Director), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
